Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

COMBI-r – A non-interventional, multi-centric, prospective trial of combined Dabrafenib and Trametinib treatment of advanced melanoma in the real-world setting - Combi-r

Next Previous
X
Search
Trial Profile

COMBI-r – A non-interventional, multi-centric, prospective trial of combined Dabrafenib and Trametinib treatment of advanced melanoma in the real-world setting - Combi-r

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabrafenib (Primary) ; Trametinib (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Combi-r
  • Sponsors Novartis Pharma

    • Most Recent Events

    • 13 Sep 2022 Status changed to completed, as per results presented at the 47th European Society for Medical Oncology Congress.
    • 13 Sep 2022 Results assessing the effectiveness and safety of dabrafenib and trametinib in patients with metastatic melanoma, presented at the 47th European Society for Medical Oncology Congress.
    • 21 Sep 2020 Interim results (n=502) presented at the 45th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top